Ifosfamide for injection

This product has no anti-cancer activity in vitro. Once it enters the body, it is hydrolyzed by phosphatase or phosphatase in the liver or tumor, and becomes active phosphoramide nitrogen mustard to take effect. Its mechanism of action may be cross-linking with DNA, inhibiting DNA synthesis, and interfering with RNA function. It is a non-specific drug for the cell cycle. This product has a broad anti-tumor spectrum and has inhibitory effects on a variety of tumors.

1. The main ingredient of this product is ifosfamide. ①Chemical name: 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxophosphine-2-oxide. ②Chemical structure: ③Molecular formula: C7H15Cl2N2O2P ④Molecular weight: 261.09

This product is white or off-white loose mass or powder.

Suitable for testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer, etc.

This product is dissolved in sterile water for injection and further diluted with 500-1000ml of 0.9% sodium chloride injection, then slowly dripped intravenously for at least 30 minutes. 　　Monotherapy intravenous injection is 1.2-2.5g/m2 per body surface area, and 5 consecutive days are one course of treatment. 　　Combination therapy intravenous injection is 1.2-2.0g/m2 per body surface area, and 5 consecutive days are one course of treatment. 　　The next course of treatment should be given 3-4 weeks apart or after blood toxicity is recovered (platelets 100000/μ1, white blood cells 4000/μ1). The maximum dose is 18g/m2. 　　To prevent bladder toxicity, a large amount of water should be consumed, 2L of fluid should be taken orally or intravenously every day. At the same time, protective agents for preventing hemorrhagic cystitis, such as mesna, should be used. Mesna dissolved in normal saline is given intravenously at the same time and 4 hours and 8 hours after administration. The usual dosage of mesna is 20% of the total daily amount of ifosfamide. The dosage for patients with impaired liver and kidney function has not been determined.

For patients who only use ifosfamide as a single agent, the dose-limiting toxicities are bone marrow suppression and urinary toxicity. The application of divided doses, large amounts of water intake, and the use of protective agents such as mesna can significantly reduce the incidence of hematuria complicated by hemorrhagic cystitis, especially macroscopic hematuria. The daily dose is 1.2g/m2 for 5 consecutive days. If leukopenia occurs, it is usually mild to moderate. Other significant side effects are alopecia, nausea, vomiting, and central nervous system toxicity.

It is contraindicated for patients with severe bone marrow suppression, those who are allergic to this product, those with bilateral ureteral obstruction, and pregnant and lactating women.

Precautions during pregnancy and lactation: Contraindicated for use by pregnant and lactating women.

(1) For patients who have previously received cisplatin, ifosfamide may aggravate the bone marrow suppression, neurotoxicity, and nephrotoxicity. (2) Concurrent use of anticoagulants may lead to the risk of bleeding. (3) Concurrent use of hypoglycemic drugs may enhance the hypoglycemic effect. (4) When used in combination with other cytotoxic drugs, the dosage should be reduced as appropriate. (5) Administration of live vaccines (such as rotavirus vaccine) while taking this drug will increase the risk of infection from the live vaccine. Patients receiving immunosuppressive chemotherapy cannot receive live vaccines. (6) Concurrent radiotherapy may aggravate the skin reactions caused by radiotherapy.

Keep in a dark and cool place (2-10℃).

1.0g

Shijiazhuang Kaida Bioengineering Co., Ltd.

• Founded in:

  1991-09-17

• Address:

  No. 198, Xiangjiang Road, Shijiazhuang High-tech Zone

• Tax NO.:

  91130101104435383N

• Registered Funds:

  3 million yuan

• Website:

  Log in to view

• Email:

  Log in to view